Law 360 M&A

MARCH 25, 2024

AbbVie Inc., million for Cooley LLP-led Landos Biopharma Inc., a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. represented by Paul Weiss Rifkind Wharton & Garrison LLP, said Monday it will pay up to $212.5

98

98

Benzinga

NOVEMBER 30, 2023

AbbVie (NYSE: ABBV ) has announced an acquisition of Immunogen (NASDAQ: IMGN ) that is expected to be completed 2024-H1. Under the terms of the agreement, AbbVie has agreed to give Immunogen $10.10 About The Companies Involved AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology.

59

59

Law 360 M&A

JANUARY 8, 2024

A shareholder alleges that ImmunoGen Inc. directors and advisers significantly undervalued the company while preparing to sell to AbbVie Inc., including by failing to consider the $1.6 billion in projected revenue from a new ovarian cancer drug, according to a suit filed Monday.

75

75

Mogin Rubin M&A

AUGUST 3, 2022

AbbVie Inc., which owns the patent on the global blockbuster drug, Humira, has again defeated a pair of claims by welfare-health plans that the company violated Sections 1 and 2 of the Sherman Antitrust Act. AbbVie Inc., 1 the Seventh Circuit U.S. 20-2402, 7 th Cir.).

98

98

Benzinga

MARCH 25, 2024

and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. NYSE: ABBV ) ("AbbVie") and Landos Biopharma, Inc. senior vice president, chief medical officer, global therapeutics, AbbVie. Under the terms of the agreement, AbbVie will acquire Landos at a price of $20.42 NORTH CHICAGO, Ill.

40

40

Benzinga

NOVEMBER 30, 2023

AbbVie Inc (NYSE: ABBV ) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN ) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. Full story available on Benzinga.com

64

64

Benzinga

SEPTEMBER 14, 2022

The increasing adoption of visually appealing lifestyle habits will create several growth opportunities for the companies operating in the market. Industry Developments: March 2020 : AbbVie Inc. Pune, India, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The global breast implant market size is projected to reach USD 3.05

Marketability 40

Marketability 40